 BOSTON, Aug. 5, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq:MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three months ended June 30, 2021 and announced recent business highlights. We continue to make important progress on developing elamipretide and our deep pipeline of novel mitochondrial-targeted compounds to address rare and devastating diseases of mitochondrial dysfunction, said Reenie McCarthy, Chief Executive Officer at Stealth. 